Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avricore Health (AVCRF) EBITDA (2016 - 2025)

Avricore Health has reported EBITDA over the past 12 years, most recently at -$324117.3 for Q4 2025.

  • Quarterly EBITDA fell 595.09% to -$324117.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$985185.4 through Dec 2025, down 1097.42% year-over-year, with the annual reading at -$990174.8 for FY2025, 1150.89% down from the prior year.
  • EBITDA was -$324117.3 for Q4 2025 at Avricore Health, down from -$275431.0 in the prior quarter.
  • Over five years, EBITDA peaked at $565162.6 in Q1 2021 and troughed at -$331765.5 in Q2 2025.
  • The 5-year median for EBITDA is -$7187.0 (2024), against an average of -$6981.8.
  • Year-over-year, EBITDA surged 2571.94% in 2021 and then plummeted 939.96% in 2025.
  • A 5-year view of EBITDA shows it stood at $165723.9 in 2021, then plummeted by 206.11% to -$175856.1 in 2022, then skyrocketed by 128.68% to $50442.8 in 2023, then rose by 29.78% to $65466.6 in 2024, then tumbled by 595.09% to -$324117.3 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's EBITDA are -$324117.3 (Q4 2025), -$275431.0 (Q3 2025), and -$331765.5 (Q2 2025).